Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406566 | 0.85 | MTNR1B (0.48) | DRD2MTNR1BPIK3CDUSP30 | |
| SCHEMBL6404916 | 0.85 | DRD2 (0.61) | DRD2MTNR1BCYP11B2 | |
| SCHEMBL6406808 | 0.82 | CNR2 (0.51) | PIK3CDCYP11B2 | |
| SCHEMBL6405018 | 0.81 | DRD2 (0.57) | DRD2MTNR1BCYP11B2 | |
| SCHEMBL6409744 | 0.81 | DRD2 (0.57) | DRD2MTNR1B | |
| SCHEMBL6404494 | 0.81 | DRD2 (0.57) | DRD2MTNR1B | |
| SCHEMBL6405122 | 0.80 | MTNR1B (0.44) | DRD2MTNR1B | |
| SCHEMBL6405877 | 0.80 | DRD2 (0.44) | DRD2MTNR1BCYP11B2 | |
| SCHEMBL6407645 | 0.79 | MTNR1B (0.43) | DRD2MTNR1B | |
| SCHEMBL6404866 | 0.78 | DRD2 (0.43) | DRD2MTNR1BPIK3CDGRIA2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | claimed |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005113527-A1 | TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | DRD2 18/4885MTNR1B 63/4885MCHR1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.